NCT03215199 (NAPT) is a NA clinical trial of NAPT in Cancer Distress, sponsored by University of Alberta.

Who is sponsoring NCT03215199?

NCT03215199 is sponsored by University of Alberta.

What drugs are being tested in NCT03215199?

Interventions in NCT03215199: NAPT.

What condition does NCT03215199 study?

NCT03215199 studies Cancer Distress.

Is NCT03215199 still recruiting?

NCT03215199 is currently recruiting now. Last updated 16 August 2024.

Last reviewed 2024-08-16 · How we verify

NCT03215199: NAPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Northern Alberta Psychosocial Telecare (NAPT) Screening for HNC Patients

Recruiting now NA Last updated 16 August 2024

What this trial tests

NA trial testing NAPT in Cancer Distress in 50 participants. Currently enrolling.

Timeline

1 September 2017

Primary endpoint
30 June 2026

30 June 2026

Quick facts

Lead sponsor	University of Alberta
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	50
Start date	1 September 2017
Primary completion	30 June 2026
Estimated completion	30 June 2026
Sites	1 location across Canada

Drugs / interventions tested

NAPT

Conditions studied

Cancer Distress — all drugs for Cancer Distress →

Sponsor

University of Alberta

Who can join

18 and older, any sex, with Cancer Distress. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized controlled trial comparing a web-based psychosocial screening application to usual care in a cohort of surgically-treated head and neck cancer patients to determine its efficacy in monitoring depression and distress, and prompting necessary psychiatry/psychology referrals. In addition, treatment adherence, rehabilitation and return to work, primary care utilization, and survival will be monitored.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Alberta trials

Trials by the same sponsor.

NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03215199 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alberta
Last refreshed: 16 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03215199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing